Clinical Trial

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Study acronym: MCI-GSH
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-04
Trial Details
NCT Number NCT07583251
Lead Sponsor Pravat Mandal
Collaborators: Robert J. Coury Family - Mylan Foundation, Inid Research Lab
Conditions Mild Cognitive Impairment (MCI)
Enrollment 9 participants
Start Date 2026-08-04
Primary Completion 2027-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-07